4598 Stock Overview
Develops anticancer drugs. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Delta-Fly Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥519.00 |
| 52 Week High | JP¥1,179.00 |
| 52 Week Low | JP¥445.00 |
| Beta | 0.057 |
| 11 Month Change | 3.59% |
| 3 Month Change | -13.93% |
| 1 Year Change | -56.50% |
| 33 Year Change | -58.15% |
| 5 Year Change | -70.58% |
| Change since IPO | -89.80% |
Recent News & Updates
Shareholder Returns
| 4598 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | -10.4% | -1.9% | -0.5% |
| 1Y | -56.5% | 16.9% | 10.8% |
Return vs Industry: 4598 underperformed the JP Biotechs industry which returned 16.9% over the past year.
Return vs Market: 4598 underperformed the JP Market which returned 10.8% over the past year.
Price Volatility
| 4598 volatility | |
|---|---|
| 4598 Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in JP Market | 7.6% |
| 10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4598's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4598's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 13 | Kiyoshi Eshima | www.delta-flypharma.co.jp |
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase III clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is in preclinical trial to treat gastric/ovarian cancer. Delta-Fly Pharma, Inc. was incorporated in 2010 and is headquartered in Tokushima, Japan.
Delta-Fly Pharma, Inc. Fundamentals Summary
| 4598 fundamental statistics | |
|---|---|
| Market cap | JP¥4.68b |
| Earnings (TTM) | -JP¥1.65b |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.8x
P/E RatioIs 4598 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4598 income statement (TTM) | |
|---|---|
| Revenue | JP¥0 |
| Cost of Revenue | JP¥0 |
| Gross Profit | JP¥0 |
| Other Expenses | JP¥1.65b |
| Earnings | -JP¥1.65b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -183.02 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 4598 perform over the long term?
See historical performance and comparison